Top Markets
#1 Akedo Akedo +73.50%
#2 MEET48 MEET48 +26.11%
#3 Bitway Bitway +21.76%
#4 VeThor VeThor +21.08%
#5 Power Protocol Power Protocol +17.38%
#6 Tutorial Tutorial +16.23%
#7 Astar Astar +14.86%
#8 龙虾 (Lobster) 龙虾 (Lobster) +12.72%
#9 Falcon Finance Falcon Finance +12.11%
#10 Arbitrum Arbitrum +12.09%
Coin of the day
Akedo Akedo
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Acticor Biotech SAS Acticor Biotech SAS

Acticor Biotech SAS

ALACT
Classifica tra le azioni #37014
Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating... Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating therapies for the acute phase of thrombotic conditions. The company's lead compound, glenzocimab, is a humanized monoclonal antibody fragment specifically designed to target a particular platelet glycoprotein. Currently, Acticor Biotech is advancing two clinical programs, both in Phase II/III, for the registration of treatments for ischemic stroke. Additionally, it is conducting two other Phase II trials concerning significant cardiovascular emergencies, with anticipated clinical data expected from both its ischemic stroke research and studies related to COVID-19 respiratory distress syndrome. Established in 2013, the company operates from its headquarters in Paris, France.
Prezzo delle azioni
$0.25974701
Ultima sincronizzazione: 2025-01-06
Capitalizzazione di mercato
$2.04M
Variazione (1 giorno)
0.74%
Variazione (1 anno)
0.00%
Paese
FR
Scambia Acticor Biotech SAS (ALACT)

Categoria

Healthcare
Utile per Acticor Biotech SAS (ALACT)
Utile nel Jun 2024 TTM: $-12.93M
Secondo gli ultimi rapporti finanziari di Acticor Biotech SAS, gli utili attuali della società sono $-12.93M. Nel 2022, la società ha registrato un utile di $-19.33M, una diminuzione rispetto a agli utili del 2021, che erano di $-16.54M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Acticor Biotech SAS dal 2010 al 2026
Utile alla fine di ogni anno
Anno Utile Cambia
2026 (TTM) $-12.93M -43.60%
2023 $-22.92M 18.60%
2022 $-19.33M 16.85%
2021 $-16.54M 50.20%
2020 $-11.01M 86.82%
2019 $-5.89M -14.36%
2018 $-6.88M -41.98%
2017 $-11.86M 2,061.40%
2016 $-548.85K -76.37%
2015 $-2.32M 97.57%
2014 $-1.18M -131.38%
2013 $3.75M -11.81%
2012 $4.25M 30.59%
2011 $3.25M 275.68%
2010 $865.72K 0.00%
Utile per aziende simili o concorrenti
Azienda Utile Differenza negli utili Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -40,906.21%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -15,190.08%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B 30,968.98%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B 23,780.79%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH